经皮微波凝固综合治疗转移性肝癌  

Percutaneous microwave coagulation comprehensive therapy for metastatic liver cancer

作　　者：沈杰[1] 马爱英[1] 刘秋如[1] 丁威[1] 王亚进[1] 

机构地区：[1]解放军第455医院肿瘤科,上海200052

出　　处：《东南国防医药》2008年第1期19-21,共3页Military Medical Journal of Southeast China

摘　　要：目的观察经皮微波凝固(PMCT)为主综合治疗转移性肝癌的疗效。方法对35例转移性肝癌,共96个目标病灶,先行肝动脉化疗栓塞术(TACE),然后在超声引导下行PMCT和经皮瘤内注射无水酒精(PEI),1个月后再进行全身静脉化疗。结果经综合治疗后,患者受益率(CR+PR+SD)为88.6%,血清肿瘤指标转阴率为75.9%(22/29),中位生存期为24.5个月,1年和2年生存率分别为91.4%、51.4%。结论以PMCT为主联合TACE、PEI和全身化疗治疗转移性肝癌是一种安全、有效、合理的综合序贯治疗模式。Objective To study the efficacy of percutaneous microwave coagulation （PMCT） comprehensive therapy for metastatic liver cancer. Methods 96 nodules of metastatic liver cancer in 35 patients were treated with transcatheter hepatic arterial chemoembolization （TACE）, and followed by ultrasound-guided PMCT and percutaneous alcohol injection（PEI）, then chemotherapy after a month. Results When the comprehensive therapies finished, response rate of patients was 88. 6%, the normalized rate of serum tumor maker was 75. 9%, median survival time was 24. 5 months, 1-year and 2-year survival rates were 91.4% and 51.4%, respectively. Conclusion The comprehensive therapy including PMCT,TACE,PEI and chemotherapy for metastatic liver cancer is a safe, effective and rational mode.

关 键 词：肝转移癌 微波凝固 化学栓塞 无水酒精 化疗 

分 类 号：R735.7[医药卫生—肿瘤]